Active Biotech provided a status update in the projects following the new direction communicated in early February. This abbreviated update is provided as a midterm replacement of the Capital Markets Day previously announced for May 19, which is now instead are planning to host during fourth quarter this year subject to the status of Covid-19. Despite the Covid-19 pandemic, most activities in the projects have proceeded according to plan and, so far, no project timelines have been significantly affected. The Phase 1b/2 study with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced solid tumors aims to establish the maximum tolerated dose of the combination before advancing to a larger cohort expansion phase in the United States. The study is enrolling according to plan and the company look forward to reviewing results from the dose escalation phase of this trial later this year. In the tasquinimod project, which is directed towards multiple myeloma, the final preparations to start the first clinical study with tasquinimod in this indication are underway. The study, which is planned to recruit up to 54 patients, will establish a maximum tolerated dose of tasquinimod alone, then investigate tasquinimod in combination with a standard multiple myeloma oral regimen of ixazomib, lenalidomide, and dexamethasone. For both single agent tasquinimod and the combination with the standard oral treatments, exploratory expansion cohorts will be enrolled to preliminarily characterize the anti-myeloma activity of each regimen. The Covid-19 pandemic has slowed down trial initiation procedures during April and May, but the advanced preparations enable to maintain the target of first patient recruited into the study during the third quarter of this year, as previously communicated. More detailed information about the study is available on clinicaltrials.gov (NCT04405167). New preclinical data on the effects of tasquinimod in experimental models of multiple myeloma, will be presented at the Virtual edition of the European Hematology Association Meeting ­ EHA, in June 11-22. Data to be presented include effects of tasquinimod alone and in combination with treatments from the compound classes that will be used in the upcoming clinical study, i.e. immunomodulatory drugs (IMiDs)and proteasome inhibitors (PIs). This work has been completed in collaboration with Dr. Yulia Nefedova and her team at the Wistar Institute, Philadelphia, US. The data will be made available through activebiotech.com in connection with the presentation. In the laquinimod project, which now is directed into a project focused towards systemic treatment of Crohn's disease, and a project focused towards topical development of a new treatment for the eye diseases uveitis and wet AMD, progress has also been realized. In Crohn's disease the company is evaluating and compiling the documentation from the previous clinical phase 2a study results prior to a regulatory advice procedure with the FDA and EMA.